ADVERTISEMENT

'Add' Mastek Shares Maintains HDFC Securities, Sees Multiple Growth Triggers Ahead

Mastek stock has corrected ~7% and 23% in the last one and three months, respectively, and is trading at a P/E of 18x and 15x FY26/27E EPS.

<div class="paragraphs"><p>Mastek stock has corrected ~7% and 23% in the last one and three months, respectively, and is trading at a P/E of 18x and 15x FY26/27E EPS. (Photo Source: pexels)</p></div>
Mastek stock has corrected ~7% and 23% in the last one and three months, respectively, and is trading at a P/E of 18x and 15x FY26/27E EPS. (Photo Source: pexels)
With a budget of ~£200 billion, NHS England is a major client for Mastek, contributing ~22% of its revenue. Mastek's management is closely monitoring these changes but does not anticipate a major impact on spending. However, there may be short-term uncertainty and delays due to the merger activities.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit